inductos
medtronic biopharma b.v. - dibotermin alfa - tibial fractures; fracture fixation, internal; spinal fusion - lyf til að meðhöndla beinsjúkdóma - sýnt er ætlað fyrir einu stigi lenda interbody hrygg samruna eins og í staðinn fyrir ígræðslu eigin bein ígræðslu í fullorðnir með hrörnunar diskur sjúkdóma sem hafa fengið að minnsta kosti 6 mánuðum ekki skurðaðgerðar fyrir þessu ástandi. sýnt er ætlað fyrir meðferð bráð sköflungur beinbrot í fullorðnir, sem viðbót til að standard sama með opið beinbrot lækkun og intramedullary unreamed nagli upptaka.
pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
influvactetra (influvac tetra) stungulyf, dreifa í áfylltri sprautu 15/15/15/15 míkróg/skammt
viatris aps - b/phuket/3073/2013-líkur stofn (b/phuket/3073/2013, villigerð); a/victoria/2570/2019 (h1n1)pdm09 - líkur stofn (a/victoria/2570/2019, ivr-215); a/darwin/9/2021 (h3n2)- líkur stofn (a/darwin/9/2021, san-010); b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - stungulyf, dreifa í áfylltri sprautu - 15/15/15/15 míkróg/skammt
berinert stungulyfs-/innrennslisstofn og leysir, lausn 500 a.e.
csl behring gmbh* - c1-hemill - stungulyfs-/innrennslisstofn og leysir, lausn - 500 a.e.
cefuroxim fresenius kabi stungulyfs-/innrennslisstofn, lausn 1500 mg
fresenius kabi ab - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1500 mg
bendamustine medac stofn fyrir innrennslisþykkni, lausn 2,5 mg/ml
medac gesellschaft für klinische spezialpräparate gmbh - bendamustinum hýdróklóríð - stofn fyrir innrennslisþykkni, lausn - 2,5 mg/ml
berinert stungulyfsstofn og leysir, lausn 1500 a.e.
csl behring gmbh* - c1-hemill - stungulyfsstofn og leysir, lausn - 1500 a.e.
berinert stungulyfsstofn og leysir, lausn 2000 a.e.
csl behring gmbh* - c1-hemill - stungulyfsstofn og leysir, lausn - 2000 a.e.
cefuroxim fresenius kabi stungulyfs-/innrennslisstofn, lausn 750 mg
fresenius kabi ab - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 750 mg
pemetrexed wh (pemetrexed synthon) innrennslisþykkni, lausn 25 mg/ml
williams & halls ehf. - pemetrexedum inn - innrennslisþykkni, lausn - 25 mg/ml